Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxyurea + azathioprine + alemtuzumab + thioptepa + low dose total body irradiation + sirolimus
- Development stage
- Unknown
- Lead developer
- Amsterdam UMC
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Oral, Intravenous, External Beam Radiation
01
Overview
A combination immunosuppressive regimen that includes multiple drugs and radiation therapy. The regimen contains hydroxyurea (an antimetabolite), azathioprine (an immunosuppressant), alemtuzumab (a monoclonal antibody), thioptepa (an alkylating agent), low dose total body irradiation (a radiation therapy), and sirolimus (an mTOR inhibitor immunosuppressant). This combination likely provides potent immunosuppression through multiple mechanisms for preventing organ rejection or treating specific conditions.
02
Targets
DNAFKBP1AMechanistic target of rapamycin complex 1RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on hydroxyurea + azathioprine + alemtuzumab + thioptepa + low dose total body irradiation + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxyurea + azathioprine + alemtuzumab + thioptepa + low dose total body irradiation + sirolimus.